New Alzheimer’s disease drug shown to slow disease
The recent approval of Leqembi (lecanemab-irmb) by the U.S. Food and Drug Administration as a treatment for Alzheimer’s disease (AD) marks the first amyloid beta-directed
Read More
Leqembi